DiPersio, John F. https://orcid.org/0000-0002-0429-3133
Koehne, Guenther https://orcid.org/0009-0008-6281-4655
Shah, Nirali N. https://orcid.org/0000-0002-8474-9080
Bernard, Léa
Suh, Hyung C.
Koura, Divya
Tamari, Roni https://orcid.org/0000-0002-2386-0850
Mushtaq, Muhammad Umair
Maakaron, Joseph
Rimando, Joseph
Kennedy, Vanessa E.
Patel, Sagar S. https://orcid.org/0000-0001-9949-3615
Hudson, Chad
Loken, Michael R.
Slapak, Christopher A.
Lloyd, Deborah M.
Stanizzi, Darren A.
Lee-Sundlov, Melissa M.
Thosar, Sanjana
Mundelboim, Guy
Guo, Guangwu
Ge, Huanying Gary
Li, Bin E.
Xavier-Ferrucio, Juliana
Hyzy, Sharon L.
Lin, Michelle I. https://orcid.org/0009-0005-9297-2855
Raffel, Glen D.
Cooper, Brenda W.
Funding for this research was provided by:
Vor Biopharma
Article History
Received: 1 August 2025
Accepted: 24 March 2026
First Online: 12 May 2026
Competing interests
: J.F.D.: equity and research funding from Wugen, Magenta Therapeutics and RiverVest Venture Partners; board member or advisory role for SPARC and Vertex; and research funding from NeoImmune Tech, Macrogenics and Bioline. G.K.: consultancy for Vor Biopharma. N.N.S.: research funding from Lentigen, Vor Biopharma and ImmunoACT Sobi; advisory board for Vor Biopharma (unpaid); and royalities from CARGO. D.K.: advisory board for Bristol Myers Squibb and research funding from Iovance Biotherapeutics. J.M.: research funding from Gilead, Atara, CRISPR Therapeutics, Precision Biosciences, Scripps Research Institute, Vor Biopharma and Affimed. V.E.K.: consultancy for Astelles and Servier. S.S.P.: advisory board for CareDx and Sobi; advisory board and speaker for Sanofi; and speakeer for Kite and Incyte. L.B., H.C.S., R.T., J.R. and B.W.C. report no conflicts of interest. C.H. and M.L. are employees of Hematologics. C.A.S., D.M.L., D.A.S., M.M.L.-S., S.T., G.M., G.G., H.G.G., B.E.L., J.X.-F., S.L.H., M.I.L. and G.D.R. were employees of Vor Biopharma when the work was conducted.